Myxomatous valve degeneration: A look  at the latest developments of the disease

Juan Pablo Reyes Mantilla; Fabian Alejandro Gómez Torres; Favio Sánchez Pico; Javier Hernando Albarracin Navas; Édgar Hernando Toledo Caceres

doi:10.16925/sp.v9i18.546

Myxomatous valve degeneration : A look at the latest developments of the disease

Revisión

https://doi.org/10.16925/sp.v9i18.546

Juan Pablo Reyes Mantilla Ver Biografía

Universidad Cooperativa de Colombia. Sede Bucaramanga.

Fabian Alejandro Gómez Torres Ver Biografía

Universidad Cooperativa de Colombia. Sede Bucaramanga.

Favio Sánchez Pico Ver Biografía

Universidad Cooperativa de Colombia. Sede Bucaramanga.

Javier Hernando Albarracin Navas Ver Biografía

Universidad Cooperativa de Colombia. Sede Bucaramanga.

Édgar Hernando Toledo Caceres Ver Biografía

Universidad Cooperativa de Colombia. Sede Bucaramanga.

This review article is an analysis of the most recent published scientific articles about myxomatous valve degeneration (MVD) and was conducted over a five month period. The aim of this review is to consolidate information about the most recent medical developments in regards to myxomatous degeneration in the mitral valve. The authors of this article reached a consensus on both the development of the disease and the most effective type of diagnosis and treatment that is available today. Myxomatous valve degeneration is the most common heart disease in the canine population. It is identified by a loss of mechanical integrity in the heart due to structural changes in the valvular components. Degenerative changes occur due to an accumulation of mucopolysaccharides in the leaflets and chordae which affect the proper operation of the valve apparatus. This is caused by faulty coaptation of the leaflets, resulting in mitral or tricuspid regurgitation, dilated ventricles and annuli, which are lesions that eventually cause the rupture of the chordae tendineae, leading to complications or possibly death. Due to the gradual progression of the disease and the presence or absence of clinical signs, it is very important that veterinarians accurately diagnose and follow-up on these patients in order to achieve stabilization and provide a suitable prognosis and treatment plan. The current ideal treatment of the disease is a low-sodium diet, administration of the aceinhibitor (angiotensin-converting-enzyme inhibitor) spironolactone and a diuretic in order to reduce the presence of pulmonary edema and avoid the progression of the disease to congestive heart failure.

Palabras clave: av valves, canine, heart, Myxomatous degeneration, treatment.

French AT, Ogden R, Eland C, Hemani G, Pong-Wong R, Corcoran B et al. Genome-wide analysis of mitral valve disease in Cavalier King Charles Spaniels. The Veterinary Journal. 2012; 193(1): 283-6.

Gordon SG, Saunders AB, Hariu CD, Boggess MM, Mi ller MW. Retrospective review of carvedilol administra tion in 38 dogs with preclinical chronic valvular heart disease. Journal of Veterinary Cardiology. 2012; 14(1): 243-52.

Reynolds CA, Brown DC, Rush JE, Fox PR, Nguyenba TP, Lehmkuhl LB et al. Prediction of first onset of con gestive heart failure in dogs with degenerative mitral valve disease: The predict cohort study. Journal of Veterinary Cardiology. 2012; 14(1): 193-202.

Aupperle H, März I, Thielebein J, Kiefer B, Kappe A, Schoon HA. Immunohistochemical characterization of the extracellular matrix in normal mitral valves and in chronic valve disease (endocardiosis) in dogs. Research in Veterinary Science. 2009; 87: 277-83.

Heaney AM, Bulmer BJ, Ross CR, Schermerhorn T. A te chnique for in vitro culture of canine valvular interstitial cells. Journal of Veterinary Cardiology. 2012; 11(1): 1-7.

Nogueira RB, Silva AC, Reis GF, Muzzi RA, Mantovani MM. Muscular arterial impedance in dogs with chronic degenerative mitral valve disease. Research in Veterinary Science. 2012; 93(3): 1434-8.

Parker HG, Kilroy-Glynn P. Myxomatous mitral valve disease in dogs: Does size matter. Journal of Veterinary Cardiology. 2012; 14(1): 19-29.

Atkins C, Bonagura J, Ettinger S, et al. acvim Consensus Statement: Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med. 2009; 23: 1142-50.

Hadiana M, Corcoran BM, Bradshaw JP. Molecular changes in fibrillar collagen in myxomatous mitral valve disease. Cardiovascular Pathology. 2010; 19(5): e141-8.

Lacerda CM, MacLea HB, Kisiday JD, Orton EC. Static and cyclic tensile strain induce myxomatous effector proteins and serotonin in canine mitral valves. Journal f Veterinary Cardiology. 2012; 14(1): 223-230.

Sacks MS, Merryman WD, Schmidt DE. On the bio mechanics of heart valve function. J Biomech. 2009; 42(12): 1804-24.

Hadian M, Corcoran BM, Han RI, Grossmann JG. Bradshaw JP. Organization in Canine Myxomatous Mi tral Valve Disease: An X-Ray Diffraction Study. Biophysical Journal. 2007; 93(7): 2472-6.

Lewis T, Swift S, Woolliams JA, Blott S. Heritability of premature mitral valve disease in Cavalier King Charles spaniels. The Veterinary Journal. 2011; 188(1): 73-6.

Borgarelli M, Savarino P, Crosara S, Santilli RA, Chia vegato D, Poggi M et al. Survival characteristics and prognostic variables of dogs with mitral regurgitation attributable to myxomatous valve disease. J Vet Intern Med. 2008; 22: 120-8.

Gómez L. Degenerative valve disease in dogs: update on diagnosis, treatment and prognosis. Rev Colomb Cienc Pecu. 2011; 24: 201-8.

Chetboul V, Tissier R. Echocardiographic assessment of canine degenerative mitral valve disease. Journal of Veterinary Cardiology. 2012; 14(1): 127-48.

Griffiths LG, Fransioli JR, Chigerwe M. Echocardiogra phic assessment of interventricular and intraventricular mechanical synchrony in normal dogs. Journal of Veterinary Cardiology. 2011; 13(2): 115-26.

Hezzell MJ, Boswood A, Moonarmart W, Elliott J. Se lected echocardiographic variables change more rapidly in dogs that die from Myxomatous mitral valve disease. Journal of Veterinary Cardiology. 2012; 14(1): 269-79.

Chetboul V, Tissier R. Echocardiographic assessment of canine degenerative mitral valve disease. Journal of Veterinary Cardiology. 2012; 14(1): 127-48.

Pedersen HD, Häggström J. Mitral valve prolapsed in the dog: a model of mitral valve prolapse in man. Cardiovasc. Res. 2000; 47: 234-43.

Buchaman JW, Bucheler J. Vertebral scale system to measure canine Heart size in radiographs. Journal of Veterinary Internal Medicine. 1995; 206: 194-9.

Richards JM, Farrar EJ, Kornreich BG, Moıse NS, But cher JT. The mechanobiology of mitral valve function, degeneration, and repair. Journal of Veterinary Cardiology. 2012; 14(1): 47-58.

Orton EC, Lacerda CM, MacLea HB. Signaling pathways in mitral valve degeneration. Journal of Veterinary Cardiology. 2012; 14(1): 7-17.

Stephens EH, Durst CA, Swanson JC, Grande-Allen KJ, Ingels JR NB, Miller C. Functional Coupling of Valvular Interstitial Cells and Collagen Via alpha2 bheta1. Cellular and Molecular Bioengineering. 2010; 3(4): 428-37.

Connell PS, Han RI, Grande-Allen KJ. Differentiating the aging of the mitral valve from human and canine myxomatous degeneration. Journal of Veterinary Cardiology. 2012; 14(1): 31-45.

Mucha CJ. Degeneración Valvular Mixomatosa. REDVET. 2007; 8(7): 1-7.

O’Leary, Wilkie I. Cardiac Valvular and Vascular Disease in Bull Terriers. Vet Pathol. 2009; 46: 1149.

Fox PR. Pathology of myxomatous mitral valve disease. Journal of Veterinary Cardiology. 2012; 14(1): 103-26.

Disatian S, Ehrhart III EJ, Zimmerman S, Orton EC. Interstitial cells from dogs with naturally-occurring myxomatous mitral valve disease undergo phenotype transformation. J Heart Valve Dis. 2008; 17(4): 402-12.

Dillon AR, Dell’Italia LJ, Tillson M, Killingsworth C, Denney T, Hathcock J. Left ventricular remodeling in preclinical experimental mitral regurgitation of dogs. Journal of Veterinary Cardiology. 2012; 14(1): 73-92.

Aupperle H, Disatian S. Pathology, protein expression and signaling in myxomatous mitral valve degenera tion: Comparison of dogs and humans. Journal of Veterinary Cardiology. 2012; 14(1): 59-71.

Braunlin EA, Harmatz PR, Scarpa M, Furlanetto B, Kampmann C, Loehr JP et al. Cardiac disease in patients with mucopolysaccharidosis: presentation, diag nosis and management. J Inherit Metab Dis. 2011; 34: 1183-97.

Aupperle H, März I, Thielebein J, Dinges G, Schoon A. Histomorphological findings and expression of matrix metalloproteinases and their tissue specific inhibitors (TIMPs) in normal tricuspid valves and in chronic tri cuspid valvular disease in dogs. The Veterinary Journal. 2010; 183: 176-83.

Borgarelli M, Buchanan JW. Historical review, epide miology and natural history of degenerative mitral valve disease. Journal of Veterinary Cardiology. 2012; 14(1): 93-101.

Gaasch WH, Meyer TE. Left Ventricular Response to Mitral Regurgitation: Implications for Management. Circulation. 2008; 118: 2298-303.

Fukunaga K, Fujii Y, Chiba N, Ueshima A, Wakao Y, Mishima K. Pharmacokinetics of nicorandil in dogs with mild mitral regurgitation. Research in Veterinary Science. 2011; 90(1): 95-8.

Kellihan HB, Stepien RL. Pulmonary hypertension in canine degenerative mitral valve disease. Journal of Veterinary Cardiology. 2012; 14(1): 149-64.

De Jong AM, Maass AH, Oberdorf-Maas SU, Van Veld huisen DJ, Van Gilst WH, Van Gelder IC. Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation. Cardiovascular Research. 2010; 89: 754-65.

Ward EE Jr. North Park Animal Hospital. 2012.

Waxman AS, Kornreich BG, Gould RA, Moise NS, But cher JT. Interactions between TGFb1 and cyclic strain in modulation of myofibroblastic differentiation of ca nine mitral valve interstitial cells in 3D culture. Journal of Veterinary Cardiology. 2012; 14: 211-21.

Boswood A. Valvular heart disease in the dog. Veterinary Focus. 2008;18(3): 25.

Atkins CE, Haggstrom J. Pharmacologic management of myxomatous mitral valve disease in dogs. Journal of Veterinary Cardiology. 2012; 14(1): 165-84.

Chandler ML. Safety: Sodium in Pet Foods. Pet Food. 008; 23(3): 148-53.

Bernay F, Bland JM, Häggstrőm J, et al. Efficacy of spiro nolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease. J Vet Intern Med. 2010; 24: 331-41.

Jeunesse E, Woehrle F, Schneider M, Lefebvre P. Effect of spironolactone on diuresis and urine sodium and po tassium excretion in healthy dogs. Journal of Veterinary Cardiology. 2007; 9(2): 63-8.

Thomason JD, Rockwell JE, Fallaw TK, Calvert CA. Influence of combined angiotensin-converting enzyme inhibitors and spironolactone on serum K, Mg2, and Na concentrations in small dogs with degenerative mitral valve disease. Journal of Veterinary Cardiology. 2007; 9(2): 103-8.

Oyama M, Peddle GD, Reynolds CA, Singletary GE. Use of the loop diuretic torsemide in three dogs with advanced heart failure. Journal of Veterinary Cardiology. 2011; 13(4): 287-92.

Peddle GD, Singletary GE, Reynolds CA, Trafny DJ, Machen MC, Oyama MA. Effect of torsemide and furo semide on clinical, laboratory, radiographic and quality of life variables in dogs with heart failure secondary to mitral valve disease. Journal of Veterinary Cardiology. 2012; 14(1): 253-9.

Atkins CE. Advances in the Management of Canine Heart Failure. Proceedings of the Congreso Latinoa mericano de Emergencia y Cuidados Intensivos LA VECCS. 2010. Disponible en: disponible http://www.laveccs.org/biblioteca/file/CHF%20Advances%2009%20LONG%20version.pdf

de Andrade J, Orton EC, Boon J, Nishimori CT, Olivaes C, Camacho AA. Partial external mitral annuloplasty in dogs with myxomatous mitral valve degeneration and heart failure: Outcome in 9 cases. Journal of Veterinary Cardiology. 2011; 13(3): 197-201.

Reyes Mantilla, J. P., Gómez Torres, F. A., Sánchez Pico, F., Albarracin Navas, J. H., & Toledo Caceres, Édgar H. (2013). Myxomatous valve degeneration: A look at the latest developments of the disease. Spei Domus, 9(18). https://doi.org/10.16925/sp.v9i18.546

Descargar cita

En calidad de autor del artículo, declaro que este, es un trabajo original, inédito, de mi creación exclusiva, que no se ha postulado a evaluación simultánea en otra publicación y que no cuenta con algún impedimento de cualquier naturaleza para la concesión de los derechos previstos en este contrato.

En ese sentido, me comprometo a esperar un resultado de evaluación de la revista, antes de considerar su presentación a otro medio, en caso de que la respuesta de publicación no sea positiva; adicionalmente, me comprometo a responder por cualquier acción de reivindicación, plagio u otra clase de reclamación que al respecto pudiera sobrevivir por parte de terceros.

Asimismo, declaro que como autor o coautor, estoy de acuerdo por completo con los contenidos presentados en este trabajo y cedo todos los derechos patrimoniales, es decir, la reproducción, comunicación pública, distribución, divulgación, transformación, puesta a disposición y demás formas de explotación de la obra por cualquier medio o procedimiento, a la revista y a la Editorial de la Universidad Cooperativa de Colombia.

Número

Vol. 9 Núm. 18 (2013)

Publicado

2013-06-01

Descargas

PDF

Cómo citar

Descargar cita

Métricas

Cargando métricas ...

https://plu.mx/plum/a/?doi=10.16925/sp.v9i18.546